HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent...
SHENZHEN, China, Jan. 27, 2025 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, announced plans to adopt...
SHANGHAI, Jan. 27, 2025 /PRNewswire/ -- On January 27th, 2025, Beijing Time, Qiming Venture Partners' portfolio company HyperStrong, a leading provider of battery energy storage...